Clinical Trial Update: A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and pharmacodynamic study of PF-04950615 (RN316) in subjects with hypercholesterolemia, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Hypercholesterolemia

Drugs mentioned

• PF-04950615 (RN316) (PF-04950615)

Snippet

Sponsor: Pfizer | Conditions: Hypercholesterolemia, Dyslipidemias | Phase 1 | Status: COMPLETED | Results posted: 2018-07-23